SuperworthXBiotech price to sales ratio XBIT
Market value divided by revenue over the last twelve months, since 2021.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 64.3×
- Nov 2023
- 6-year median
- 15.0×
- 6-year range
- 9.3× to 87.0×
- Peer median
- 1.5×
XBiotech's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Nov 2023, at 64.3×.
On the days it had one over the last 6 years, its median was 15.0×, from 9.3× in Oct 2022 to 87.0× in Aug 2023.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2023 | 64.3× | 11.9× | 87.0× |
| 2022 | 13.0× | 9.3× | 18.4× |
| 2021 | 17.7× | 11.3× | 23.4× |
Against its peers
Companies in Drug Manufacturers - General nearest XBiotech's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| XBITXBiotech | n/m |
| SPROSpero Therapeutics | 1.4× |
| ATNMActinium Pharmaceuticals | n/m |
| LFVNLifevantage | 0.4× |
| NATRNatures Sunshine Products | 0.4× |
| ARVNArvinas | 1.5× |
| PBYIPuma Biotechnology | 2.5× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.3× |
| Peer median | 1.5× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on XBiotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.